By contrast, the DC1 dendritic cell vaccine is ideal in that it appears to inhibit rather than activate T cell-mediated suppression and may carry the added benefit of converting these cells into tumor-reactive effectors. This evidence concerns the gene ZDHHC4 and neoplasm.